BioSpace

J&J’s innovative medicines carried Q3 as medtech disappoints, but newer medicines absent

While innovative medicine supported Johnson & Johnson’s “in line” earnings for the third quarter of 2026, investors were disappointed to see older medicines carrying the bag.

By BioSpace

1 min read
J&J’s innovative medicines carried Q3 as medtech disappoints, but newer medicines absent
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights